KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLiabilities from Discontinued OperationsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

TherapeuticsMD (TXMD) Other Non-Current Liabilities (2020 - 2025)

TherapeuticsMD's Other Non-Current Liabilities history spans 8 years, with the latest figure at $873000.0 for Q4 2025.

  • For Q4 2025, Other Non-Current Liabilities rose 17.34% year-over-year to $873000.0; the TTM value through Dec 2025 reached $873000.0, up 17.34%, while the annual FY2025 figure was $873000.0, 17.34% up from the prior year.
  • Other Non-Current Liabilities reached $873000.0 in Q4 2025 per TXMD's latest filing, roughly flat from $871000.0 in the prior quarter.
  • In the past five years, Other Non-Current Liabilities ranged from a high of $2.1 million in Q4 2021 to a low of $358000.0 in Q2 2021.
  • Average Other Non-Current Liabilities over 5 years is $890157.9, with a median of $795000.0 recorded in 2025.
  • Peak YoY movement for Other Non-Current Liabilities: surged 2065.71% in 2021, then crashed 48.25% in 2022.
  • A 5-year view of Other Non-Current Liabilities shows it stood at $2.1 million in 2021, then plummeted by 48.25% to $1.1 million in 2022, then tumbled by 42.55% to $636000.0 in 2023, then grew by 16.98% to $744000.0 in 2024, then rose by 17.34% to $873000.0 in 2025.
  • Per Business Quant, the three most recent readings for TXMD's Other Non-Current Liabilities are $873000.0 (Q4 2025), $871000.0 (Q3 2025), and $832000.0 (Q2 2025).